PHILADELPHIA – An implantable brain device that literally melts away at a pre-determined rate minimizes injury to tissue normally associated with standard electrode implantation, according to research led by a team from the Perelman School of Medicine at the University of Pennsylvania. The researchers describe online in Nature Materials a new class of technology that provides greater resolution for measuring electrical activity in space and time that matches or exceeds existing methods.
Thin, flexible neural electrode arrays with fully bioresorbable construction based on patterned silicon nanomembranes (Si NMs) as the conducting component.
Credit: The lab of Brian Litt, MD, Perelman School of Medicine, University of Pennsylvania
“Dissolvable silicon electronics offer an unprecedented opportunity to implant advanced monitoring systems that eliminate the risks, cost, and discomfort associated with surgery to extract current devices used for post-operative monitoring,” said senior co-author Brian Litt, MD, a professor of Neurology, Neurosurgery, and Bioengineering. Litt co-led the study with long-time collaborator John A. Rogers, PhD, a material scientist from the University of Illinois at Urbana-Champaign. “This study tested the usefulness of temporary, dissolvable monitoring systems capable of providing continuous streams of data for guiding medical care over predetermined periods of time -- from days to months -- before dissolving.”
The device is made of layers of silicon and molybdenum that can measure physiological characteristics and dissolve at a known rate, as determined by its thickness. For example, the team used the device to record brain waves in rats under anesthesia, as well as voltage fluctuations between neurons (EEGs), and induced epileptic spikes in intact live tissue. A separate experiment demonstrated a complex, multiplexed array made from these materials that could map rat-whisker sensing capabilities at high resolution.
These electrophysiological signals were recorded from devices placed at the surface of the brain cortex (the outer layer of tissue) and the inner space between the scalp and skull. Chronic measurements were made over a 30-day period, while acute experiments demonstrated device operations over three to four hours.
The type of neurophysiologic features measured by the new device are commonly used for diagnosing and treating such disorders as epilepsy, Parkinson's disease, depression, chronic pain, and conditions of the peripheral nervous system. “These measurements are critically important for mapping and monitoring brain function during and in preparation for neurosurgery, for assisting in device placement, such as for Parkinson's disease, and for guiding surgical procedures on complex, interconnected nerve structures,” Litt said.
Other applications include post-operative monitoring and recording of physiological characteristic after minimally invasive placement of vascular, cardiac, orthopaedic, neural or other devices. At present, post-operative monitoring is based on clinical examination or interventional radiology, which is invasive, expensive, and impractical for continuous monitoring over days to months.
Comparative studies showed that the new sensor performed as well or better relative to conventional electrodes used in the clinic, with regard to tissue reactivity as measured by tissue pathology, as well as cellular and immune staining after the studies’ end.
The team sees many uses for this new technology. “We also want to develop this implant to monitor post-operative seizures and recovery of brain function after surgery,” Litt said.
“Recent evidence suggests that up to three months of intracranial recording may be required to adequately locate seizures before epilepsy surgery or device placement. This is a period of time that is prohibitively long for existing in-hospital approaches. Using our dissolvable electrodes for this situation would eliminate the danger and cost of removing electrodes.”
These devices could also be used by heart and brain surgeons for such applications as aneurysm coiling, stent placement, embolization, and endoscopic operations. These new devices could monitor structures that are exposed during surgery but are too delicate to disturb after initial operations to remove devices. Currently, monitoring after many procedures is done remotely from surgical sites, with variable results.
The team next plans to develop more complex devices that include flow, pressure, and other measurement capabilities, in addition to electrical recording, and test them in animal models of disease, before moving into human testing.
This work was funded by the Defense Advanced Research Projects Agency, the Penn Medicine Neuroscience Center, a T32- Brain Injury Research Training Grant
(5T32NS043126-12), the Mirowski Family Foundation, and by Neil and Barbara Smit.
Co-authors are Ki Jun Yu, Duygu Kuzum, Suk-Won Hwang, Bong Hoon Kim, Halvor Juul, Nam Heon Kim, Sang Min Won, Ken Chiang, Michael Trumpis, Andrew G. Richardson, Huanyu Cheng,Hui Fang, Marissa Thompson, Hank Bink, Delia Talos, Kyung Jin Seo, Hee Nam Lee, Seung-Kyun Kang, Jae-Hwan Kim, Jung Yup Lee, Younggang Huang, Frances E. Jensen, Marc A. Dichter, and Timothy H. Lucas.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.